Breast Cancer Clinical Trial
— SEINIOROfficial title:
Quality of Life and Breast Cancer in Older Women
Background :
Breast cancer is a disease that occurs primarily in elderly women: 54057 of breast cancer
occurred on women in 2008, 15.2% were between 75 and 84 years and 5.4% were over 85 years.
Elderly women cancers care exposes to several problems: the opportunity for screening,
knowing that mammography is not recommended after 75 years old, and the level of treatment
depending on the background and the existence of weaknesses. It should determine whether
patients are in adequate physiological condition to tolerate classical and "complete"
treatment or conversely in a precarious state with advanced fragility, justifying only
lightened and adapted symptomatic treatment.
Purpose :
The purpose of this research theme is to assess the quality of life of elderly patients who
underwent mastectomy for breast cancer. The objectives are:
- Assess the determinants of acceptance and / or rejection of mastectomy based on personal
background (level of fragility, self-image) and linked to cancer
- Assess the quality of life, 6 months later, of women who underwent or not mastectomy,
and appreciate the determinants
Abstract :
The total mastectomy allow, oncologically, a more valid treatment than a lumpectomy, in many
cases of women suffering from a breast cancer, but its relevance and acceptability are poorly
known. Some think that an elderly woman, postmenopausal, is less concerned with her
aesthetics and feminine attributes, which would allow her to accept easily the mastectomy.
The research hypothesis is that the acceptability of mastectomy is not good in elderly women
| Status | Recruiting |
| Enrollment | 174 |
| Est. completion date | December 15, 2020 |
| Est. primary completion date | December 15, 2020 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 75 Years to 100 Years |
| Eligibility |
Inclusion Criteria: 1. Elderly patients about or over 75 years 2. Female 3. Patients in whom a diagnosis of breast cancer with surgical indication for mastectomy with or without lymph node dissection is discussed 4. Ability to understand and give freely consent 5. Informed consent signed 6. Patient affiliated to the social security or entitled Exclusion Criteria: 1. Patients under 75 years 2. Male 3. Patients under legal protection |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Hospitalier de Saint-Quentin; | Saint-Quentin | Aisne |
| Lead Sponsor | Collaborator |
|---|---|
| Central Hospital Saint Quentin |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Evaluation of quality of life change by SF-36 (The Short Form Health Survey) between baseline and six months | the 36-Item Short Form Health Survey (SF-36). SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and are now widely utilized monitoring and assessment of care outcomes in adult patients. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability |
Baseline and 6 months | |
| Secondary | QLQ-C30 (Global Health Status) | Quality of life (QoL or QOL) is the perceived quality of an individual's daily life, that is, an assessment of their well-being or lack thereof. This includes all emotional, social and physical aspects of the individual's life;All of the scales and single-item measures range in score from 0 to 100. | Baseline and 6 months | |
| Secondary | Psychological profile | Big Five Inventory (BFI),personality inventory for research settings, minimum = 45 points and maximum scores = 180 points . | Baseline and 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |